A saliva test taken by parents to screen for the leading infectious cause of hearing loss in babies was feasible and well-received, according to a new study.
The research led by the Murdoch Children’s Research Institute (MCRI) and published in the Journal of Paediatrics and Child Health, could pave the way for testing of congenital cytomegalovirus (cCMV) to be added to infant hearing screening programs across Australia.
cCMV can be harmless, but in some babies, it leads to hearing loss and neurodevelopmental disorders such as cerebral palsy or vision loss. About 1 in every 200 babies is born with cCMV.
MCRI researcher Emma Webb says this was the first study to show saliva swabs taken by parents to check for cCMV in their babies was achievable and acceptable to Australian families, even when the swabs were taken at home after discharge from the hospital.
The study involved 96 families across four maternity hospitals in Melbourne whose babies did not pass their second Victorian Infant Hearing Screening Program (VIHSP) tests. Accurate diagnosis of cCMV requires a saliva test from an infant in the first 21 days after birth, with antiviral treatment recommended, if clinically indicated, within the first month of life.
During the study, 26% of parents did the saliva test at home, 60% at the hospital and 10% as outpatients. The research found a high uptake by parents with 76% agreeing to do the screen and 100% of infant saliva swabs taken within the required time-frame. One baby was found to have cCMV and was immediately treated.
The findings also showed more than 90% of parents thought the screening was easy to do, was a good idea, and were glad their baby had the test.
Webb says CMV was present in 80% of Australian adults and while it’s mostly harmless, it could affect a developing fetus.
“Once a person becomes infected, the virus remains present but usually dormant for life,” she says. “Infection or reactivation can occur during pregnancy, with the small risk that the unborn baby may contract the virus.”
International guidelines recommend targeted cCMV screening of newborns who do not pass their hearing checks.
MCRI Associate Professor Valerie Sung, PhD, says because cCMV was not routinely screened for in Australia, detecting affected infants in time to offer potential antiviral treatment was less likely.
“Given this test allows for an early and accurate cCMV diagnosis, could reduce unnecessary parental guilt, and help prevent lifelong disabilities, it should be rolled out nation-wide through newborn hearing screening programs,” she says.
Sung also says timely screening for cCMV became more difficult after women and babies were discharged.
“Early discharge, as we’re seeing more now of during COVID-19, can be a big problem because it means we might miss cases of cCMV,” she says. “But our study has shown parents can do the swab themselves even at home after leaving the hospital.”
Sung believes training hearing screeners, midwives and nurses to complete swabs in the hospital would likely reduce false positive rates and further improve the uptake and turnaround time for results.
Victoria Cottrell, whose son Teddy was the only one to test positive for cCMV in the trial, says the test was quick and simple and taking part was the best decision.
“I had never heard of cCMV before and thought the cause of the hearing loss most likely was genetic,” she says. “During my pregnancy check-ups, many infant conditions and foods to steer clear from were mentioned, but cCMV was never talked about. The diagnosis came as a shock and was a lot for our family to process.”
Teddy, now aged two, wears cochlear implants — and underwent six months of antiviral treatments. He currently has physiotherapy to help with walking.
“If his cCMV diagnosis wasn’t picked up so soon, he would be further behind in his gross motor skills,” Cottrell says. “Having the awareness early, we have received support quickly and our specialists have been on top everything.”
Cottrell says she would like to see a test for cCMV added to infant hearing screening programs across Australia.
“If the trial hadn’t happened, we would never have known Teddy had cCMV,” she says. “I’m just so thankful and relieved that this trial existed to get the best outcomes for Teddy.”
Sung, meanwhile, has also received a grant from the National Health and Medical Research Council (NHMRC) to trial a new technology, which can be turned into a rapid bedside test, to detect cCMV and determine how common it is in newborns without hearing loss. The results will be used to determine whether universal newborn cCMV screening is warranted. The trial intends to use data from the Gen V research project — one of the world’s largest-ever birth and parent cohort studies.
Researchers from the University of Melbourne, The Royal Children’s Hospital, Monash University, Mercy Hospital for Women, The Royal Women’s Hospital, Western Health, Monash Children’s Hospital, Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, The University of Sydney and the Sydney Children’s Hospital Network also contributed to the study.
Featured Image: A saliva test taken by parents to screen for the leading infectious cause of hearing loss in babies was feasible and well-received, according to a new study. Photo: Filip Mroz